Presentation Slides
Back to course
Pdf Summary
transitional age youth
serious mental illnesses
off-label use
informed consent process
FDA-registered indications
risk mitigation
treatment-resistant schizophrenia
first episode psychosis
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
Powered By